BioClever selected Flex Databases eTMF and PM & Budgeting 

November 16, 2021

BioClever selected Flex Databases eTMF and PM & Budgeting 

This fall BioClever, Spanish full-service CRO, and Flex Databases signed a contract for eTMFProject Management & Budgeting and Time Sheets & Utilization implementation.

We’ve asked Jordi Cantoni, Director at BioClever a couple of questions about the new partnership:

Why BioClever decided to implement eTMF, Project Management & Budgeting, Time Sheets & Utilization?

The main reason to decide to move to a global platform was the company improvement. With the implementation of Flex Databases in our company, we expect a significant improvement into the efficiency and effectiveness, as well as an easiest and better standardization of management tasks.

Why BioClever selected Flex Databases as a software provider?

After comparing different solutions to manager our company, we decided to select Flex Databases for three main reasons:

  • The possibility to manage all aspects of our company with a unique software solution.
  • The specialization in clinical trials and studies. Same language-talking.
  • The friendly front user and utilization.

What do you expect to achieve with the implementation of Flex Databases?

We are totally convinced that the implementation of Flex Databases will allow us to achieve a higher level of quality, improve efficiency and effectiveness, and a very important point, greater transparency and communication with our clients.

A total control of ours projects, in terms of resources dedication will be also improved and totally controlled will Flex Databases.

BioClever is a provider of outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and health organizations.

We focus our efforts on the factors that are critical to our clients – reducing times, reducing cost and increasing quality –our team of experts has extensive experience in a broad range of therapeutic areas.

Blog

July 7, 2026
Is Your EDC Really Modern If Someone Still Has to Re-Enter Every Serious Adverse Event?

Clinical industry has finally embraced AI, sponsors run decentralized trials and data is now collected in real time. But still one of the most critical workflows in every study – handling adverse events (AEs) – surprisingly depends on copy-paste. Most sponsors assume that if they have an Electronic Data Capture (EDC) system and a Pharmacovigilance […]

June 30, 2026
Validating AI in GxP Environments: The Flex Databases Approach to eTMF Compliance

The pharmaceutical industry faces a familiar paradox: the tools that promise to make regulatory compliance faster and smarter also introduce the most complex new compliance questions. Nowhere is this more visible than in AI-powered Trial Master File (TMF) management. At Flex Databases, we have developed a validation framework rooted in GxP principles, risk-based thinking, and […]

June 25, 2026
The Quiet Revolution in TMF: How AI Document Classification Turns Routine into a Background Task

AI in Trial Master File management has quietly stopped being a someday idea. It’s not a pilot and it’s not a roadmap promise – it’s something clinical teams reach for on an ordinary Tuesday. The interesting part isn’t that AI can file a document; it’s how calmly and predictably it does it now – with […]

June 24, 2026
Investigator Site File Management with Flex Databases

Managing Investigator Site Files across multiple sites is one of the more operationally demanding aspects of clinical trial oversight. Flex Databases addresses this with a dedicated ISF module built around three distinct user experiences (Sponsor, CRA, and Site) each tailored to the workflows and priorities of its audience. The Sponsor View: Study-Wide Visibility Sponsors access […]

Contact us

Get in touch to discuss compliance, implementation, demos, pricing

We are here for all of your questions! Tell us more about yourself and we will organize a tailored live demo to show how you can power up your clinical trials processes with Flex Databases.